Intellia Therapeutics Hits Day High with 29.81% Surge in Stock Price

Intellia Therapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced significant activity today, with its stock surging by 29.81% on September 18, 2025. The stock reached an intraday high of USD 16.38, marking a notable milestone in its trading performance.
In terms of performance metrics, Intellia has shown a remarkable 94.57% increase over the past day, significantly outperforming the S&P 500, which saw a slight decline of 0.1%. Over the past week, the stock has risen by 109.49%, while its one-month performance stands at 98.4%. However, it is important to note that the stock has faced challenges over the longer term, with a one-year performance decline of 30.8% compared to the S&P 500's gain of 17.14%.

Despite today's gains, Intellia's financial health reflects ongoing concerns, including a negative EBITDA and a return on equity of -65.26%. The company has also reported a significant operating cash flow deficit and declining net sales. As it navigates these challenges, Intellia Therapeutics remains a focal point in the biotechnology landscape.